Omeros Corp (OMER): Cash & Equivalents
$9.66M
As of 2025-12-31
$1.99M
As of 2026-06-30
-4.3%
3-year compound annual growth
-1.7%
5-year compound annual growth
+21.6%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.66M | +184.1% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $3.40M | -52.1% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $7.11M | -35.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $11.01M | -89.1% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $100.81M | +860.0% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $10.50M | +240.5% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $3.08M | -47.4% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $5.86M | +72.7% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $3.39M | +52.6% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $2.22M | +62.9% | 2019-03-01, Balance as of period end |
| 2015-12-31 | $1.36M | +285.6% | 2018-03-01, Balance as of period end |
| 2014-12-31 | $354.0K | -74.4% | 2017-03-16, Balance as of period end |
| 2013-12-31 | $1.38M | -8.9% | 2016-03-15, Balance as of period end |
| 2012-12-31 | $1.52M | -62.0% | 2015-03-16, Balance as of period end |
| 2011-12-31 | $4.00M | +22.2% | 2014-03-13, Balance as of period end |
| 2010-12-31 | $3.28M | +299.8% | 2013-03-18, Balance as of period end |
| 2009-12-31 | $820.0K | n/a | 2012-03-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Omeros Corp (OMER) | 2025-12-31 | $9.66M | +184.1% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $58.45M | +54.7% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $307.53M | -34.8% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $41.32M | -18.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $190.68M | +8.0% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $261.34M | +4.2% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $77.56M | -52.6% |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $226.65M | +192.9% |
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | $45.54M | -38.7% |
Compare OMER, SION, PRTA, SPRY side by side · Screen every company in Pharmaceutical Preparations ↗